Equity Profile

EXEL

Exelixis, Inc.

Health CareBiotechnology$13.2B

May5Tue

Post-Earnings Recap

ReportedQ1-2026After Close4:05 PM EDT

Exelixis Beats on EPS, Stock Up 0.57%

Metric	Actual	Expected	Surprise
EPS	$0.87	$0.76	+29.27%
Revenue	—	$605M	—

management commentary, guidance changes, and full analysis available with Pro.

Exelixis Beats on EPS, Stock Up 0.57%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$0.87	$0.76	+29.27%
Revenue	—	$605M	—

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based solely on numerical results.

What It Means

Exelixis reported a strong earnings per share, exceeding analyst expectations significantly. However, there was no revenue reported, which leaves some uncertainty about the company's performance. The stock reacted positively, increasing by 0.57%, likely driven by the better-than-expected EPS figure.

Company Snapshot

Exelixis, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for cancer treatment....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.

$0.76

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$605M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Exelixis, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for cancer treatment. Operating in the health care sector, Exelixis plays a crucial role in addressing unmet medical needs in oncology, which is a significant area of focus given the rising incidence of cancer worldwide.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+57.79%

Avg Stock Reaction

-0.79%

Last Quarter Recap

In Q4 2025, Exelixis reported an EPS of $0.94, significantly exceeding estimates. However, the stock experienced a decline of 2.21% the following day, indicating mixed market reactions.

Management Promises & Guidance

Continued focus on expanding its oncology portfolio.
Commitment to enhancing operational efficiency.
Plans to explore new market opportunities.

Expectations

Wall Street Expectations

Analysts are generally optimistic about Exelixis's upcoming earnings, expecting solid EPS and revenue figures. However, there are concerns about potential market volatility following the results.

Bull Case

If Exelixis beats earnings expectations, it could signal strong demand for its products and lead to positive investor sentiment.

Bear Case

Conversely, if the company fails to meet expectations, it may raise doubts about its growth prospects and lead to a decline in stock price.

Key Metrics to Watch

EPS

$0.76

Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.

Revenue

$605M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Exelixis achieve an EPS of $0.76 or higher?

This figure is crucial as it reflects the company's profitability and can significantly influence investor sentiment.

What are the revenue expectations for the quarter?

Revenue performance will indicate market demand for Exelixis's products and its growth trajectory.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Exelixis to exceed EPS expectations due to strong demand for its oncology products.

Supporting Evidence

Exelixis has consistently beaten EPS estimates in recent quarters.

The options market is pricing a larger move than historical averages suggest.

Recent trends in oncology treatments indicate a growing market for Exelixis's offerings.

Key Risk

If revenue comes in below $583M, it could undermine confidence in the company's growth prospects.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching Exelixis's ability to meet or exceed earnings expectations, which will be pivotal for its stock performance.

Bull Confirmed If

An EPS of $0.80 or higher would confirm strong operational performance and growth potential.

Bear Confirmed If

An EPS below $0.69 would raise concerns about the company's profitability and market position.

Pre-Earnings Positioning

Options Market

Implied Move

±7.1%

Historical Avg

±1.1%

Pricing rich

The options market is pricing in a significant move, suggesting that investors anticipate volatility around the earnings release.

Options are pricing ±9.1% while EXEL has averaged ±1.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

31.2%

Calls (32K)P/C Ratio: 0.65Puts (21K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: X of Y (Z%)

This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 4.6%, with a raw directional average of +0.8% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Exelixis beats expectations, history suggests a potential stock increase of around 0.81%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further commentary.

Miss

Should the company miss expectations, history indicates a likely decline of about 1.14%, raising concerns about future growth.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new product launches in the oncology space.
2Any changes to guidance for future quarters.
3Insights on market demand for existing therapies.
4Details on operational efficiencies and cost management.
5Management's outlook on competitive pressures in the biotechnology sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

GRABReported

Grab Holdings Limited

RecapView

May4

GBDCReported

Company Snapshot

Exelixis, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for cancer treatment....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.

$0.76

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$605M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+57.79%

Avg Stock Reaction

-0.79%

Last Quarter Recap

In Q4 2025, Exelixis reported an EPS of $0.94, significantly exceeding estimates. However, the stock experienced a decline of 2.21% the following day, indicating mixed market reactions.

Management Promises & Guidance

Continued focus on expanding its oncology portfolio.
Commitment to enhancing operational efficiency.
Plans to explore new market opportunities.

Expectations

Wall Street Expectations

Analysts are generally optimistic about Exelixis's upcoming earnings, expecting solid EPS and revenue figures. However, there are concerns about potential market volatility following the results.

Bull Case

If Exelixis beats earnings expectations, it could signal strong demand for its products and lead to positive investor sentiment.

Bear Case

Conversely, if the company fails to meet expectations, it may raise doubts about its growth prospects and lead to a decline in stock price.

Key Metrics to Watch

EPS

$0.76

Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.

Revenue

$605M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Exelixis achieve an EPS of $0.76 or higher?

This figure is crucial as it reflects the company's profitability and can significantly influence investor sentiment.

What are the revenue expectations for the quarter?

Revenue performance will indicate market demand for Exelixis's products and its growth trajectory.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Exelixis to exceed EPS expectations due to strong demand for its oncology products.

Supporting Evidence

Exelixis has consistently beaten EPS estimates in recent quarters.

The options market is pricing a larger move than historical averages suggest.

Recent trends in oncology treatments indicate a growing market for Exelixis's offerings.

Key Risk

If revenue comes in below $583M, it could undermine confidence in the company's growth prospects.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching Exelixis's ability to meet or exceed earnings expectations, which will be pivotal for its stock performance.

Bull Confirmed If

An EPS of $0.80 or higher would confirm strong operational performance and growth potential.

Bear Confirmed If

An EPS below $0.69 would raise concerns about the company's profitability and market position.

Pre-Earnings Positioning

Options Market

Implied Move

±7.1%

Historical Avg

±1.1%

Pricing rich

The options market is pricing in a significant move, suggesting that investors anticipate volatility around the earnings release.

Options are pricing ±9.1% while EXEL has averaged ±1.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

31.2%

Calls (32K)P/C Ratio: 0.65Puts (21K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: X of Y (Z%)

This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 4.6%, with a raw directional average of +0.8% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Exelixis beats expectations, history suggests a potential stock increase of around 0.81%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further commentary.

Miss

Should the company miss expectations, history indicates a likely decline of about 1.14%, raising concerns about future growth.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new product launches in the oncology space.
2Any changes to guidance for future quarters.
3Insights on market demand for existing therapies.
4Details on operational efficiencies and cost management.
5Management's outlook on competitive pressures in the biotechnology sector.